BRAF and melanoma: In conclusion, these results demonstrate that C‐terminal Hsp90 inhibitors can overcome several chemo‐resistance pathways activated with MEK and BRAF inhibitor resistance in melanomas while simultaneously inhibiting critical pro‐survival pathways, especially those involving the cell cycle and oxidative phosphorylation.